In the news release, FDA Approves FILKRI™ (filgrastim-laha), Accord BioPharma's Biosimilar to NEUPOGEN® (filgrastim), issued 17-Feb-2026 by Accord BioPharma over PR Newswire, we are advised by the ...
Although previous work has found lower costs for biosimilar filgrastim compared with reference filgrastim, this study found that site of care can change this calculus, reducing savings. Objectives: ...
Clinical data from randomized studies demonstrated that Filkri is highly similar to the reference product with no clinically meaningful differences in safety, pharmacokinetics, or immunogenicity. The ...
“The U.S. approval of our first biosimilar is a very significant milestone for Amneal. Biosimilars represent the next wave of providing access to affordable medicines in the U.S.” Chirag and Chintu ...
Releuko ® (filgrastim-ayow), a biosimilar to Neupogen ® (filgrastim), is now available in the US for the treatment of neutropenia. Releuko, a leukocyte growth factor, is indicated to: Decrease the ...
PISCATAWAY, N.J.--(BUSINESS WIRE)--U.S.-based Adello Biologics today announced that U.S. Food and Drug Administration (FDA) has accepted for review the company’s Biologics License Application (BLA) ...
The U.S. FDA approved three biosimilar products from Samsung Bioepis Co. Ltd., Tanvex Biopharma Inc. and Formycon AG as follow-on biologics to Stelara (ustekinumab), Neupogen (filgrastim) and Eylea ...
This is an ASCO Meeting Abstract from the 2021 ASCO Quality Care Symposium. This abstract does not include a full text component.
Prospective study comparing Broviac cuffed catheter and implantable vascular access device for adjuvant and neoadjuvant chemotherapy for breast cancer : infectious and mechanical risks This is an ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results